

Curriculum Vitae

Holger Sültmann Professor, Dr. rer. nat.
d.o.b. August 13, 1962, in Köln, Germany

University Education

2001 Habilitation in *Genetics*, Tübingen University
1994 Dr. rer. nat., Max-Planck-Institute for Biology and Tübingen University
1991 Diploma in Biochemistry, Tübingen University
1983–1991 Studies of Chemistry and Biochemistry, Tübingen University, Germany

Scientific Career

Since 2012 Full professor for *Cancer Genome Research*, Faculty for Medicine, Heidelberg University, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK) and National Center for Tumor Diseases (NCT), Heidelberg
Since 2019 Scientific Head, Dieter Morszeck Biorepository, DKFZ, Heidelberg
2010–2017 Member of the International Scientific Steering Committee of the International Cancer Genome Consortium (ICGC)
Since 2010 Independent Group and Division Head *Cancer Genome Research*, DKFZ and NCT, Heidelberg
2000–2010 Assistant Professor, DKFZ, Heidelberg, Div. *Molecular Genome Analysis* (Prof. Dr. Annemarie Poustka)
1996–2000 Assistant Professor, Max-Planck-Institute for Biology (MPI-B), Tübingen, Div. *Immunogenetics* (Prof. Dr. Jan Klein)
1994–1996 Postdoctoral Fellow, MPI-B, Tübingen Div. *Immunogenetics* (Prof. Dr. Jan Klein)

Awards and Honors

Since 2017 DKTK professorship, Faculty for Medicine, Heidelberg University
2012–2017 Endowed professorship for *Cancer Genome Research*, Faculty for Medicine, Heidelberg University, Bruno und Helene Jöster Stiftung
2009 Call for professorship for *Molecular Urology*, Erlangen University (not accepted)
2009 2nd position, professorship for *Molecular Urooncology*, Heidelberg University
2009 2nd position, professorship for *Genomics*, Mannheim University for Applied Sciences

Citation Record

Total citations: 18,763; h-index: 64 (Google Scholar July 5th, 2024)

Top-10 selected Publications

Angeles AK, Janke F, Daum AK, Reck M, Schneider MA, Thomas N, Christopoulos P, **Sültmann H**. Integrated circulating tumor DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma. *Brit J Cancer* 2023; 129(1):112-121; Apr 29. doi: [10.1038/s41416-023-02284-0](https://doi.org/10.1038/s41416-023-02284-0)

Janke F, Angeles AK, Riediger AL, Bauer S, Reck M, Schneider MA, Muley T, Thomas M, Christopoulos P, **Sültmann H**. Monitoring progression of ALK-rearranged lung adenocarcinoma using DNA methylation patterns in cell free DNA. *Clinical Epigenetics* 2022, 14(1):163. doi: [10.1186/s13148-022-01387-4](https://doi.org/10.1186/s13148-022-01387-4)

Heitzer E, van den Broek D, Denis MG, Hofman P, Hubank M, Moulière F, Paz-Ares L, Schuurig E, **Sültmann H**, Vainer G, Verstraaten E, de Visser L, Cortinovis D. Recommendations for a practical implementation of circulating tumour DNA mutation testing in metastatic non-small cell lung cancer. *ESMO Open* 2022, 7(2):100399. doi: [10.1016/j.esmoop.2022.100399](https://doi.org/10.1016/j.esmoop.2022.100399)

Angeles AK*, Christopoulos P*, Yuan Z, Bauer S, Janke F, Ogrodnik SJ, Reck M, Schlesner M, Meister M, Schneider MA, Dietz S, Stenzinger A, Thomas M, **Sültmann H**. Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis. NPJ Precision Oncology 2021, 5(1):100, DOI 10.1038/s41698-021-00239-3. doi: [10.1038/s41698-021-00239-3](https://doi.org/10.1038/s41698-021-00239-3)

The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 2020, 578(7793), 82-93. doi: [10.1038/s41586-020-1969-6](https://doi.org/10.1038/s41586-020-1969-6)

Zapatka M, Borozan I, Brewer, DS, Iskar M, Grundhoff A, Alawi M, Desai N, **Sültmann H**, Moch H, PCAWG Pathogens Working Group, ICGC/TCGA Pan-cancer Analysis of Whole Genomes Network, Cooper CS, Eils R, Ferretti V, Lichter P. The landscape of viral associations in human cancer. Nature Genetics 2020, 52(3):320-330. doi: [10.1038/s41588-019-0558-9](https://doi.org/10.1038/s41588-019-0558-9)

Gerhäuser C*, Favero F*, Risch T*, Simon R*, Feuerbach L*, Assenov Y*, Heckmann D*, Sidiropoulos N, Waszak SM, Hübschmann D, Urbanucci A, Girma EG, Kuryshev V, Klimczak L, Saini N, Stütz A, Weichenhan D, Böttcher LM, Toth R, Hendriksen JD, Koop C, Lutsik P, Matzk S, Warnatz HJ, Amstislavskiy V, Feuerstein C, Raeder B, Bogatyrova O, Schmitz E-M, Hube-Magg C, Kluth M, Huland H, Graefen M, Lawerenz C, Henry GC, Yamaguchi TN, Malewska A, Meiners J, Schilling D, Reisinger E, Eils R, Schlesner M, Strand DW, Bristow RG, Boutros P, von Kalle C, Gordenin D **Sültmann H** #, Brors B#, Plass C#, Yaspo M-L#, Korbel JO#, Schlomm T#, Weischenfeldt J#. Molecular evolution of early onset prostate cancer identifies novel molecular risk markers and clinical trajectories. Cancer Cell 2018, 10;34(6):996-1011. doi: [10.1016/j.ccell.2018.10.016](https://doi.org/10.1016/j.ccell.2018.10.016)

Riediger AL*, Dietz S*, Schirmer U, Meister M, Heinzmann-Groth I, Schneider M, Muley T, Thomas M, **Sültmann H**. Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients. Scientific Reports 2016, 6:33505. doi: [10.1038/srep33505](https://doi.org/10.1038/srep33505)

Boer J, Huber W, **Sültmann H**, Wilmer F, von Heydebreck A, Haas S, Korn B, Gunawan B, Vente A, Füzesi L, Vingron M, Poustka A. Identification and classification of differentially expressed genes in renal cell carcinoma by hybridization on a human 31,500 element cDNA array. Genome Research 2001, 11(11), 1861-1870. doi: [10.1101/gr.184501](https://doi.org/10.1101/gr.184501)

Sültmann H, Sato A, Murray BW, Takezaki N, Geisler R, Rauch GJ, Klein J. Conservation of Mhc Class III Region Synteny Between Zebrafish and Human as Determined by Radiation Hybrid Mapping. J Immunol 2000, 165, 6984-6993. doi: [10.4049/jimmunol.165.12.6984](https://doi.org/10.4049/jimmunol.165.12.6984)